Dr. Agro is an internationally recognized clinical development expert with more than 25 years of experience in IBD, Diabetes, and CNS New Drug Applications and approvals. Most recently, Albert was the Chief Medical Officer for Cynapsus Therapeutics, a specialty pharma CNS company that developed the first successful sublingual apomorphine thin strip for Parkinson’s disease. At Cynapsus, he was instrumental in initializing the company’s IPO, NASDAQ listing, and US$640 million acquisition by Sunovion Pharmaceuticals.
Albert is also the Co-Founder of GRi Bio, a clinical-stage company in NASH. He has held executive positions at Versanum (CEO), Cynapsus (CMO), Ironshore Pharma (CMO), Trillium Therapeutics Inc. (CMO), Stem Cell Therapeutics (CMO) and TransTech Pharma (EVP), and has facilitated the successful licensing of major assets to Pfizer ($3 Billion), Forest Labs ($1.05 billion), Novo Nordisk and Merck.
He serves as Director at Saint Elizabeth Health Care and has maintained a position as Professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario since September 1996. He is the recipient of a Michael J. Fox Foundation Clinical Scholarship for his work on Apomorphine. He is an Undergraduate of Iowa State University, University of Guelph. Albert holds a Ph.D. from Department of Medicine at McMaster University in 1995 and a post-doctoral fellowship from University of Florence in Italy.
Dr. Hall started his career at Abbott Laboratories working in the immunology franchise assigned to Humira (adalimumab) and assumed leadership roles with increasing responsibility, including U.S. rheumatology medical affairs lead. After leaving Abbott, Dr. Hall joined the metabolic bone clinical development team at Amgen Inc. working to launch the first monoclonal antibody, Prolia (denosumab), in primary care, for the treatment of post-menopausal osteoporosis. During this time, he was also responsible for the male osteoporosis registrational program which resulted in successful global regulatory approvals. He next joined Ardea Biosciences, a wholly owned subsidiary of AstraZeneca where he led various departments including early development and pharmacovigilance. Dr. Hall earned a BA from the University of San Diego. He received his medical degree from the University of Oklahoma and conducted his surgical training at the Medical College of Pennsylvania and Hahnemann University.
Andrew is the Chief Financial Officer and Corporate Secretary of Sublimity Therapeutics. Prior to Sublimity, he was the Chief Financial Officer of Realist Pharma, an early-stage immunotherapy company developing products to activate the innate immune system, thereby targeting immune failure which lies at the root of many diseases, including cancers and infectious diseases. Andrew is also the co-founder and former Chief Operating Officer and Chief Financial Officer of Cynapsus Therapeutics, a specialty CNS pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson’s disease. In 2016, Cynapsus was acquired for US$640 million in cash by Sunovion Pharmaceuticals, a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. While acting as CFO, Cynapsus raised approximately US$150 million primarily via private placements and public offerings, including a $72.5 million US IPO and NASDAQ listing in June 2015. Andrew earned an M.B.A. from the Richard Ivey School of Business at the University of Western Ontario (1999 to 2001), and a B.A. (Honors) in Economics from Queen’s University (1990 to 1994). He also attended the Emerging Chief Financial Officer (ECFO) Program at the Stanford University Graduate School of Business (2016).
Stephen is a former partner at Roadmap Capital acting as the firm’s healthcare subject matter expert. During his tenure he and his 3 partners invested $150 million in 8 portfolio companies from the US and Canada. Formerly, senior vice-president business development at TransTech Pharma, Stephen was involved in the pharmaceutical, specialty pharmaceutical and biotech industries for more than 30 years. He managed transactions in 2006 and 2010 with Pfizer and Forest Laboratories, respectively, valued in excess of $2 billion in potential upfront fees and milestones each with recurring double-digit royalties. Stephen brings international experience in business development, clinical development, research, sales, marketing, and executive management to Sublimity Therapeutics. He received his Bachelor of Science with Honours, Major in Biological Sciences from Brock University, St. Catharines, Ontario, Canada
Dr. Maclean has a background of more than 25 years Global Product Development and Regulatory Affairs in biologics, biotech and small molecules having worked in big-pharma, start-ups and CROs. More recently Dr. Maclean was the Vice President Global Regulatory Affairs at Cynapsus and the Senior Vice President of Scientific and Regulatory Affairs at Apotex Inc. (Canada).
Dr. Maclean also headed up the Regulatory team at Eidetica Biopharma (a division of Biogen), developing biosimilar products and as the VP Product Development then becoming the CEO of DrugAbuse Sciences (Paris) leading the full development team for a 505(b)2 reformulation of naltrexone (sold to elbion NV). Dr. Maclean has also held positions of increasing responsibility at Powderject (acquired by Chiron), SangStat Medical Inc. (acquired by Genzymne), Sanofi and Generics UK (acquired by Merck KGaA).
Ross’ experience spans the entire product life-cycle with focus both on novel development compounds as well as life cycle defensive generic strategies. He brings broad pharmaceutical therapeutic expertise with a focus on immunology, CNS, cardiovascular, pain, generics and hospital specialty products with a proven record of success of achieving product regulatory approvals. Ross brings strong agency exposure including the FDA (OND and OGD), EMEA/EMA including COMP/CHMP, various EU national agencies including MHRA, IMB, BfArM & PEI, MPA, AFSSAPS, CBG, DKMA), Health Canada/TPD and the TGA.
Ross holds a Bsc (Hons) from the University of Southampton (UK) and also completed a PhD at the same University in Pharmacology, sponsored by Laboratories Servier, France.
Bruce has 25 years of experience in clinical research and clinical development. His clinical development career started at Boehringer Ingelheim, where he worked on several programs including Spiriva®. His career has included senior management positions at clinical development consulting companies, managing programs in various therapeutic areas for Biotech and Pharma clients. A focus of his career has included the effective management of Biotech start-ups. Prior to Sublimity, he was Vice President of Clinical Development at Cynapsus Therapeutics, which was acquired by Sunovion Pharmaceuticals in 2016 for US$640 million.
Dr. McDonald has over 15 years of experience in the pharmaceutical industry with a background steeped in formulation development. He joined the company in 2005, was a co-inventor of the SmPill® technology and was centrally involved in the development of the ST-0529 formulation. Bernard has lead the Quality department at Sublimity since 2009 achieving an exemplary regulatory inspection and filing record which culminated in a $64M investment in the company in 2018.
Prior to Sublimity, Bernard held biotechnology roles focusing on monoclonal antibody and recombinant protein production with Lonza Biologics and Biouetikon.
Bernard holds a B.Sc in Biotechnology from Dublin City University (DCU), an M.Sc in Pharmaceutical Technology from Trinity College Dublin (TCD) and a PgDip in Manufacturing Pharmaceutical Technology (QP Qualification) from TCD. During his time with Sublimity, he also completed a PhD in Drug Delivery at DCU focusing on the use of the SmPill® technology for the treatment and prevention of colorectal cancer.
Dr. Mónica Rosa has over 12 years’ experience in senior positions within the pharmaceutical industry and brings expertise in formulation, research, product and process development, IP management, clinical development, business development and executive management to Sublimity Therapeutics. She joined the company in 2009, was a lead inventor of the SmPill® technology and played a key role in the development of ST-059.
Mónica led the Product Development and Production Department, overseeing all projects from early stage development to clinical manufacturing while successfully meeting internal and external product development requirements. Dr. Rosa was instrumental in securing research funds throughout her time in Sublimity culminating with the recent $64M investment in the company in 2018.
Monica holds a PhD from the University of Coimbra, an MBA from Henley Business School and has authored over 40 publications (poster and oral presentation abstracts and international journals) and two book chapters.
Mr. Shelly has over 25 years of experience in the pharmaceutical sector.
In 2001, he founded and served as Managing Director of Cambridge Clinical Research, one of the UK’s leading site management services (SMO) providers. The company provided embedded research infrastructure to Academic and NHS clinicians, and was the forerunner to the Dept. of Health’s NIHR initiative of clinical research networks. Clients included Merck, Novartis, Pfizer, Roche, Glaxo Smith Kline, Eli Lilly, Bayer PLC, Covance, ICON, INCR, PAREXEL, PPD, and Quintiles, among others.
Prior to founding CCR, Tom was Vice President of Operations and Finance at Tecan, a world-leading supplier of automation and liquid handling solutions for drug discovery in the pharmaceutical industry, clinical reference labs, and blood banks; the company’s main market was in the United States.
Tom is an MBA from Kenan Flagler Business School at the University of North Carolina, USA, a Fellow of the Institute of Chartered Accountants in Ireland, and earned his BComm from University College Dublin.
- Anthony Giovinazzo, MBA Executive Chairman
- Albert Agro, PhD President and Chief Executive Officer
- Alexander Asam, PhD
- Josh Richardson, MD
- David Bonita, MD
- Michael Parker
- Roderick Ryan
William J. Sandborn, MD
Professor of Medicine and Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Vice Chair for Clinical Operations, Department of Medicine
Director, UCSD IBD Center, UC San Diego Health System
Ken Croitoru MDCM FRCP(C)
Professor of Medicine and Immunology
University of Toronto
Division of Gastroenterology
Mount Sinai Hospital
Peter Ernst, DVM, PhD
Director of Comparative Pathology and Medicine
Co-Director of the UC Veterinary Medicine Center, San Diego
Sublimity has a strategic collaboration with Dr. Falk Pharma GmbH that includes development funding, milestone payments and tiered royalties for the future development and commercialization of ST-0529 and related products in Europe.
Dr. Falk Pharma GmbH is one of the leading companies worldwide in gastroenterology with its products being sold in more than 60 countries. The company’s pharmaceuticals are used successfully to treat inflammatory bowel disease, cholestatic liver disease, irritable bowel syndrome, constipation, and for colon cleansing prior to colonoscopies.
Sublimity has a partnered with Pharmascience for development and commercialization of ST-0529 and related products in Canada.
Pharmascience Inc. is a full-service, privately owned pharmaceutical company that has strong roots in Canada and a growing global reach, with product distribution in over 60 countries.